Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.83 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19176334 | 0.91 | BTK (1.00) | BTKEGFRLCK | |
| SCHEMBL21330734 | 0.91 | BTK (1.00) | BTKEGFRLCK | |
| SCHEMBL31302943 | 0.91 | BTK (1.00) | BTKEGFRLCK | |
| SCHEMBL21340179 | 0.91 | BTK (1.00) | BTKEGFRLCK | |
| SCHEMBL22018928 | 0.86 | EGFR (0.79) | BTKEGFRLCK | |
| SCHEMBL19150661 | 0.85 | BTK (1.00) | BTKEGFRLCK | |
| SCHEMBL21330699 | 0.85 | BTK (1.00) | BTKEGFRLCK | |
| SCHEMBL19176200 | 0.83 | BTK (1.00) | BTKEGFRLCK | |
| SCHEMBL21330720 | 0.83 | BTK (1.00) | BTKEGFRLCK | |
| SCHEMBL19148615 | 0.81 | BTK (1.00) | BTKEGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662187-B2 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662187-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | BTK 1/4885EGFR 210/4885LCK 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.